BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jun 1, 2024
Data Byte

EMA’s CHMP recommends new indications for Dupixent, Skyrizi

May decisions also include CStone’s PD-1 inhibitor and Pfizer’s Factor IX gene therapy
BioCentury | Mar 26, 2024
Deals

Deals Report: Week’s M&A includes AZ-Fusion, Novo Nordisk-Cardior

Plus: Intellia deciding to step back from co-developing Factor-IX therapy with Regeneron and GSK returns Sosei’s GPR35 agonist after deprioritization
BioCentury | Feb 22, 2023
Regulation

Feb. 21 Quick Takes: Crossovers back Hemab in $135M series B

Plus: FDA reviewing Onpattro for larger ATTR indication; EU gets first hemophilia B gene therapy; and updates from Merck, Pfizer and more
BioCentury | Jan 3, 2023
Data Byte

Hemophilia B competition builds with Pfizer gene therapy data

Different vectors lead to comparable improvements in bleeding in Phase III studies
BioCentury | Dec 13, 2022
Product Development

Dec. 12 Quick Takes: Setbacks at ASH for Adicet and Lava 

Plus: Updates from Magenta, CSL, Hemgenix, Affimed, Kymera and more
BioCentury | Nov 22, 2022
Regulation

CSL pushes pricing limits with first hemophilia B gene therapy approval

CSL is setting a $3.5 million price for the first hemophilia B gene therapy to reach the market
BioCentury | Aug 8, 2022
Deals

Pfizer promises expanded global reach for sickle cell drug in $5.4B GBT takeout

Pharma gains rights to Oxbryta along with a sickle cell pipeline that could deliver $3B in peak sales
BioCentury | May 25, 2022
Finance

May 24 Quick Takes: Duke Street Bio debuts to develop PARP inhibitors

Plus Alvotech’s Stelara biosimilar demonstrates bioequivalence and updates from uniQure, CSL, Alpine and more
BioCentury | Dec 9, 2021
Product Development

Welcome win for gene therapy as uniQure hits mark in hemophilia B

uniQure and partner CSL to submit regulatory applications next half
BioCentury | Mar 29, 2021
Product Development

March 29 Quick Takes: Humanigen mAb meets COVID endpoint; plus Merck, Wave, Celldex, Ionis, Orphazyme and uniQure

Humanigen Inc. (NASDAQ:HGEN) shares rose 54% to $21.61 Monday after the company said top-line data showed lenzilumab improved survival without the need for mechanical ventilation in hospitalized
Items per page:
1 - 10 of 416